Bachem Holding Market capitalization 2024

The Bachem Holding Market capitalization history

YEAR	REVENUE (undefined CHF)	GROSS MARGIN (%)	NET INCOME (undefined CHF)
2029e	1.59	11,10	333.3
2028e	1.35	13,07	307.54
2027e	1.15	15,35	257.55
2026e	1.03	17,21	191.08
2025e	0.82	21,69	153.9
2024e	0.64	27,62	115
2023	0.58	30,65	111.86
2022	0.53	32,21	100.68
2021	0.5	33,13	114.68
2020	0.4	32,07	78.06
2019	0.31	29,48	54.16
2018	0.28	29,46	46.64
2017	0.26	31,62	41.77
2016	0.24	32,67	41.21
2015	0.21	33,79	31.84
2014	0.18	34,36	29.07
2013	0.17	34,95	23.6
2012	0.16	32,45	15.56
2011	0.15	29,59	9.41
2010	0.15	34,36	28.3
2009	0.18	49,87	46.06
2008	0.19	54,94	58.71
2007	0.2	55,37	63.93
2006	0.17	53,11	46.65
2005	0.15	86,76	39.38
2004	0.15	85,42	30.71

Bachem Holding Aktienanalyse

What does Bachem Holding do?

The Bachem Holding AG is a leading provider of peptides and biochemical agents for the pharmaceutical and biotechnological industry. The company was founded in 1971 in Bubendorf, Switzerland, and has been listed on the Swiss stock exchange since 1998. The company's history began with the founding of Bachem Chemie GmbH by Peter Grogg, a former chemical engineer at Ciba-Geigy. Grogg started the company with a focus on peptide synthesis, an area that was still in its infancy at the time. Over time, Bachem expanded its core business by entering into other areas such as peptide formulation, plant extract manufacturing, and nucleotide synthesis. Today, the company has around 1,400 employees worldwide and operates production and research facilities in Europe, North America, and Asia. Bachem is considered one of the largest peptide manufacturers globally and supplies customers in over 100 countries. The business model of Bachem Holding AG is heavily focused on research and development (R&D). The company invests approximately 15% of its revenue annually in R&D to maintain and expand its leading position in peptide chemistry and biochemical agents. These investments have allowed Bachem to offer a wide range of products and services that meet various customer requirements. The company operates several business segments, including peptides and biochemicals, pharmaceutical contract manufacturing and GMP manufacturing, generic drugs, research services, and products for the diagnostics market. The peptides and biochemicals segment is the core of the company and includes a wide range of peptides, amino acids, peptide libraries, peptide-drug conjugates, synthetic proteins, and bioactive peptides. Bachem also manufactures synthetic peptide kits and customized peptides for research and development. The company is also active in pharmaceutical contract manufacturing, offering customized manufacturing services for bioactive peptides, synthetic drugs, oligonucleotides, and drug-drug conjugates. Customers can benefit from synthesis development to commercial production of active substances. Bachem has also positioned itself in the generic drug market, offering a wide range of peptide-based generics such as buserelin, leuprorelin, and triptorelin. The generic drugs segment was expanded in 2015 through the acquisition of the American biotechnology company American Peptide Company. In addition to manufacturing peptides and biochemical agents, Bachem also provides research services, including peptide synthesis, peptide conjugation with drugs, analysis of protein-protein interactions, and identification of peptide libraries. The company is also active in the diagnostics market, offering a wide range of peptides and antibodies for use in diagnostic products for research and clinical applications. In summary, the Bachem Holding AG is a leading provider of peptides and biochemical agents for the pharmaceutical and biotechnological industry. The company heavily invests in research and development and offers a wide range of products and services to meet various customer requirements. Bachem Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Bachem Holding's Market Capitalization

Bachem Holding's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Bachem Holding's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Bachem Holding's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Bachem Holding’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Bachem Holding Stock

What is the current Bachem Holding market capitalization?

The current market capitalization of Bachem Holding is 6.16 B CHF.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Bachem Holding.

How has the market capitalization of Bachem Holding developed in recent years?

The market capitalization of Bachem Holding has increased/decreased by 9.86% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Bachem Holding?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Bachem Holding?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Bachem Holding have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Bachem Holding pay?

Over the past 12 months, Bachem Holding paid a dividend of 0.37 CHF . This corresponds to a dividend yield of about 0.45 %. For the coming 12 months, Bachem Holding is expected to pay a dividend of 0.39 CHF.

What is the dividend yield of Bachem Holding?

The current dividend yield of Bachem Holding is 0.45 %.

When does Bachem Holding pay dividends?

Bachem Holding pays a quarterly dividend. This is distributed in the months of May, May, May, May.

How secure is the dividend of Bachem Holding?

Bachem Holding paid dividends every year for the past 26 years.

What is the dividend of Bachem Holding?

For the upcoming 12 months, dividends amounting to 0.39 CHF are expected. This corresponds to a dividend yield of 0.47 %.

In which sector is Bachem Holding located?

Bachem Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bachem Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bachem Holding from 4/30/2024 amounting to 0.4 CHF, you needed to have the stock in your portfolio before the ex-date on 4/26/2024.

When did Bachem Holding pay the last dividend?

The last dividend was paid out on 4/30/2024.

What was the dividend of Bachem Holding in the year 2023?

In the year 2023, Bachem Holding distributed 0.35 CHF as dividends.

In which currency does Bachem Holding pay out the dividend?

The dividends of Bachem Holding are distributed in CHF.